Stocks · News reference
OPKO Health, Inc. announced it will report its financial and operating results for the third quarter of 2026 on November 4, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
OPKO Health announced that its subsidiary, OPKO Biologics, has initiated a first-in-human Phase 1/2a clinical trial for OPK-8801001, a long-acting growth hormone receptor antagonist for acromegaly.
Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
Piper Sandler analyst Edward Tenthoff reiterates OPKO Health (NASDAQ:OPK) with a Overweight and raises the price target from $3 to $4.